Rakuten Medical

Rakuten Medical Logo

PRNewswire

Home > PRNewswire

Rakuten Medical Investigational Anti-cancer Therapy Candidate Seen to Activate Immune System Response and Synergize with PD1 Checkpoint Blockade in Animal Models

SAN MATEO, November 9, 2019 /PRNewswire/

Rakuten Medical, Inc. (RMI) a clinical-stage, global biotechnology company developing precision-targeted cancer therapies based on Rakuten Medical’s Illuminox™, its proprietary, anti-cancer treatment platform, introduced new preclinical data suggesting CD25 photoimmunotherapy (PIT) treatment, combined with…

Rakuten Medical Releases New, Post-hoc Analysis of Safety, Pharmacokinetic (PK), Immunogenicity and Biomarker Data from its Phase 1 & 1/2a Clinical Trials

SAN MATEO, September 30, 2019 /PRNewswire/

Rakuten Medical, a clinical-stage, global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox™, released post-hoc analysis of safety, pharmacokinetic (PK), immunogenicity and exploratory biomarker data from its RM-1929 photoimmunotherapy (PIT)…

Rakuten Medical Secures Additional Investment from Rakuten to Further Develop its Photoimmunotherapy Platform Capabilities Investment to also support pipeline growth, and global business and commercial expansion

SAN MATEO, August 1, 2019 /PRNewswire/

Rakuten Medical, Inc., a clinical-stage, global biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy (PIT) platform, has raised approximately US $100 million on July 31, 2019, in a Series C-1 Preferred…

CONTACT US

Rakuten Medical 900 Concar Dr., 2nd Floor
San Mateo, CA 94402 USA
info@rakuten-med.com
Tel. 858-925-5619

FOLLOW US

Linkedin

© Rakuten Medical Inc.
2019, All rights reserved.

Privacy Policy

People
×
Innovation
×
Action
×
A Note from Our Chairman

In 2012, my father was diagnosed with pancreatic cancer. I was ready to do anything for him to be cured. With that sole purpose, I read many scientific papers from all over the world, and I met and talked with numerous experts in the field. How could I cure my father’s cancer? I searched every single possibility available.

That is when I found out about photoimmunotherapy that was only at an early stage of research. Although I had many doubts about this completely new approach, desperate for a miracle, I immediately went to meet the researcher.

Everyone was still doubtful at that stage. But the more I heard about this research, the more it made sense. 

I instinctively thought, “This is it.” It was the same feeling I got as when I grasped that the internet would change the world forever. Somehow, wishing to save my father, I immediately made up my mind to support the research personally to speed it up.

Unfortunately, we didn’t make it in time to save my father. But I decided to continue my support. My father who was as an economist always said, “One important mission of corporations is to contribute to humanity.”

Left behind, I resolved to provide this latest treatment to as many people as possible. It will surely be a path fraught with difficulties. But right at this moment there are many who are suffering from cancer, many who wish to save the lives of their loved ones, and I know exactly how they feel.

To provide this treatment as soon as possible, to bring this treatment to as many people as possible, I will not fail to support this research from now on.

Chairman, Rakuten Medical, Inc.

Hiroshi Mikitani

×